












226Evidence of B Cell Immune Responses to Acute
Lymphoblastic Leukemia in Murine Allogeneic
Hematopoietic Stem Cell Transplantation Recipients
Treated with Donor Lymphocyte Infusion
and/or Vaccination
Craig A. Mullen,1 Andrew Campbell,1 Olena Tkachenko,1 Johan Jansson,1,2 Yu-chiao Hsu1These experiments explored mechanisms of control of acute lymphoblastic leukemia (ALL) following alloge-
neic hematopoietic stem cell transplantation using a murine model of MHC-matched, minor histocompati-
bility antigen–mismatched transplantation. The central hypothesis examined was that addition of active
vaccination against leukemia cells would substantially increase the effectiveness of allogeneic donor lympho-
cyte infusion (DLI) against ALL present in the host after transplantation. Although vaccination did increase
the magnitude of type I T cell responses against leukemia cells associated with DLI, it did not lead to substan-
tial improvement in long-term survival. Analysis of immunologic mechanisms of leukemia progression dem-
onstrated that the failure of vaccination was not because of antigen loss in leukemia cells. However, analysis of
survival provided surprising findings that, in addition to very modest type I T cell responses, a B cell response
that produced antibodies that bind leukemia cells was found in long-term survivors. The risk of death from
leukemiawas significantly lower in recipients that had higher levels of such antibodies. These studies raise the
hypothesis that stimulation of B cell responses after transplantation may provide a novel way to enhance
allogeneic graft-versus-leukemia effects associated with transplantation.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is performed for high-risk acute lymphoblastic
leukemia (ALL). Relapse of ALL remains the most
commoncauseof treatment failure after transplantation.
Although augmentation of graft-versus-leukemia
(GVL) effects by withdrawal of immunosuppression
and DLI is often effective in treating early relapse of
chronic myelogenous leukemia after transplantation,
these maneuvers are rarely successful in treatment1Department of Pediatrics, University of Rochester,
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6/j.bbmt.2010.08.021of ALL [1,2]. The mechanisms of the relative
ineffectiveness of DLI and GVL activity in ALL are
not fully known. Some of the possibilities include
rapid expansion of ALL cells in vivo and poor
immunogenicity of ALL cells compared to chronic
myeloid leukemia (CML) cells.
Prior work in our laboratory has demonstrated
that administration of cellular leukemia vaccines to
allogeneic transplant recipients can increase GVL
effects without substantial increases in graft-versus-
host disease (GVHD) [3,4]. We have also observed
that vaccination at the time of allogeneic lymphocyte
infusion can result in a significant expansion of
antigen specific T cells in vivo [5]. Based on these
findings, we hypothesized that vaccination coupled
with donor lymphocyte infusion (DLI) might produce
more effective control of ALL after transplantation.
The reasoning for this was that active vaccination
would provide more effective antigen presentation of
antigens present on ALL cells, and that the clonal ex-
pansion of leukemia-reactive T cells might be more ef-
fective in controlling ALL populations that have
a rapid expansion rate.
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employed a well-characterized murine model of major
histocompatibility complex (MHC)-matched, multi-
ple minor histocompatibility antigen–mismatched
transplantation [6], and novel murine pre-B ALL cell
lines driven by common human mutations (bcr/abl fu-
sion genes and Ink/ARF locus deletions) [7]. Although
many of the minor histocompatibility antigens in this
system are known at a genetic and peptide level [6], an-
tigens relatively selectively expressed on the leukemia
cells are not. To address this methodologic limitation
we exploited sex mismatches, because male HY anti-
gens are known at a genetic and peptide level. By using
ALL cells derived frommales and using female donors
and recipients we were able to use the male HY anti-
gens as models for leukemia-restricted antigens [8].
We discovered that although concurrent vaccina-
tion did increase the activity of donor T cells that rec-
ognized HY antigens on the leukemias and did have
a short-term impact on leukemia expansion, significant
survival advantages were not seen by the addition of
vaccination toDLI. Aswe investigated themechanisms
of relapse and immune control of ALL in this model,
we discovered that long-term survival after allogeneic
transplant and ALL challenge were associated with
modest T responses, and surprisingly, B cell responses
to leukemia cells.MATERIALS AND METHODS
Mice
C3.SW mice (Jackson, West Grove, PA) were
transplant donors, and C57BL/6 mice (National Can-
cer Institute, Frederick, MD) were recipients. The
mice are MHC antigen matched (H2b) but minor his-
tocompatibility antigen (mHA) mismatched at many
loci (H1, H3, H7, H8, H9, H13). C3.SW are H2b
and were derived from an 11-generation backcross of
C3H against a noninbred H2b donor strain [9].Cell Lines
NSTY pre-B ALLs were generated from primary
marrow cells from INK4A/ARF null mice transduced
with a retroviral vector encoding the human p210 bcr/
abl cDNA [7,10]. The MSCV-BCR/ABL-IRES-GFP
vector was kindly provided by Dr. Richard Van Etten.
The neo gene was removed from this vector by diges-
tion with Nco I and Cla I, and the YFP gene was
inserted by standard cloning procedure to yield the
MSCV-Nup98/HoxA9-YFP vector used in the pres-
ent study. Retroviral vector plasmids were transfected
into phoenix-eco cells (ATCC, Rockville, MD) using
lipofectamine 2000 per manufacturer’s instructions
(10 mg DNA per 100,000 cells in a 6-well tissue culture
dish). At 36 hours posttransfection, viral supernatantswere collected, filtered, and stored at280C. Retrovi-
rus-treated marrow cells (2  105) were infused intra-
venously (i.v.) into irradiated (600 cGy) C57BL/6
recipients, and spontaneous ALLs emerged within 3
weeks. NSTY lines were derived by in vitro culture
of splenocytes from these leukemia-bearing mice; no
cytokine supplementation was required [11,12]. The
male and female acute myeloid leukemia lines
(mAML and fAML, respectively) were derived from
C57BL/6 male or female mice infused with wild-type
syngeneic C57BL/6 marrow transduced in vitro with
vectors encoding p210 bcr/abl and NUP98/HOXA9
[10,12]. C1498 (ATCC) is a spontaneous C57BL/6
acute NKT cell leukemia [13]. ASLN cells were
derived from a C57BL/6 transgenic mouse created
by insertion of a C57BL/6 oocyte of a human p190
bcr/abl cDNA under the control of the immunoglob-
ulin heavy chain enhancer E-mu and the murine Mb-1
promoter [7]. YAC (TIB-160, ATCC) is an A/Sn strain
lymphoma line that is sensitive to NK cells and is the
conventional target in murine NK cytolysis assays.
P815 cells are a DBA/2 strain (H2d) mastocytoma
(TIB-64, ATCC).
Reisolation of Leukemia Cells
At time of euthanasia or death, BMT recipient
splenocytes were placed in short-term culture to allow
outgrowth of relapsing ALL cells. One week later,
aliquots of cells were cryopreserved. For subsequent
analysis, aliquots were thawed, grown in culture for
several days, and then used as target cells in leukemia
cell inhibition assays.
Bone Marrow Transplant
Following 800 cGy TBI (given in 2 equal divided
doses 14-16 hours apart) and intraperitoneal (i.p.)
5-fluoruracil (0.5mg)C57BL/6 recipientswere infused
with 4  106 marrow cells plus 10  106 splenocytes
from normal C57BL/6 mice or C3.SW mice immu-
nized against C57BL/6 splenocytes. They were housed
in conventional rooms with food and water ad libitum.
From 2 days before BMT until day 14, the water was
acidified (pH 2.5) and supplemented with 2 g/L neo-
mycin sulfate (Sigma, St. Louis, MO). We and other
investigators have observed that with use ofC3.SWdo-
nors (with 5-10 106T cells in the graft) andC57BL/6
recipients, fatal GVHD is observed in a significant
number of recipients over a 6-week period [14]. In ex-
periments in which leukemia progression in vivo was
measured, C57BL/6 mice underwent myeloablation
with radiation and 5-FU and then were simultaneously
infused with 4  106 bone marrow cells, 1  107 sple-
nocytes, and 1  104 NSTY-1 ALL cells. The source
of splenocytes varied between experimental groups,
with some recipients receivingmarrow and spleen cells
from C3.SW mice that had been vaccinated against
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whereas other control mice received cells from
C3.SW that had not been vaccinated or from normal
C57BL/6 mice.DLI and Vaccination
Donor lymphocytes were prepared from female
C3.SWmice that had been primed against HY antigens
by vaccination with irradiated male C3.SW cells.
CD90.2 cells were enriched by positive selection from
spleen cells using paramagnetically labeled CD90.2
monoclonal antibodies and positive selection columns
(Miltenyi Biotech, Auburn, CA). Cells (5  106) were
suspended in Hanks balanced salt solution and intrave-
nously infused. Vaccinations consisted of 5  106 50
Gy irradiated male C57BL/6 spleen cells or male
C57BL/6 ALL cells suspended in 0.1 mL complete
Freund’s adjuvant containing0.2mgmurine granulocyte
macrophage-colony stimulating factor (GM-CSF).Assessment of GVHD
Animals were judged to have GVHD in vivo if they
exhibited extensive hair loss and/or wasting and if at
necropsy did not have evidence of leukemia progression
(eg, splenomegaly, lymphadenopathy, and/or flow cyto-
metric measurement of leukemia in marrow or spleen).
In this strain combination, liver GVHD can be mea-
sured fairly objectively by assessment of the number of
portal triads with lymphocytic infiltration in liver sam-
ples stained with hematoxylin and eosin.Generation of Alloreactive T Cells
C3.SWmice were vaccinated subcutaneously (s.c.)
with 107 25 Gy–irradiated splenocytes 2 to 3 times at
2-week intervals. Splenocytes from C3.SW mice im-
munized against C57BL/6 splenocytes were restimu-
lated in vitro 4 days at a 5:3 ratio at 107 cells/mL
with 25 Gy–irradiated C57BL/6 splenocytes that ex-
press all the known minor histocompatibility antigens.
In other experiments designed to generate CTL with
a single specificity for 1 minor antigen peptide,
C3.SW responder cells were stimulated with synge-
neic C3.SW splenocytes preincubated with exogenous
minor histocompatibility antigen peptide. Cells were
incubated at 37C in R10S medium (RPMI, 10% fetal
calf serum [FCS], 200 mM glutamine, 104 U/mL pen-
icillin/streptomycin, nonessential amino acids [1 mL
per 100 mL medium], 100 mM Na pyruvate, and 50
mM beta-mercaptoethanol). No cytokines were added
to the culture. T cells generated from these cultures
were used as effector cells with target leukemia cells,
and a flow cytometry–based leukemia cell inhibition
assay was used to measure the capacity of the effector
cells to inhibit the leukemia target cells.Leukemia Cell Inhibition Assay
The assaymeasures the relative size of leukemia tar-
get cell populations cocultured for 3 days with potential
cytolytic effector cells inmicrocultures in 96-well plates.
Five thousand target cells were placed with effector cells
at specified effector-to-target cells ratios. Following 3
days of culture, 4000fluorescentmicrobeadswere added
to each well, and immediately thereafter, the well was
harvested and examined flow cytometrically. Regions
were defined corresponding to the beads and viable
leukemia cells, and the number of events in each region
was recorded. The number of viable leukemia cells in
a well was calculated using the following formula:
(leukemia cells in well) 5 (leukemia cells counted) 
(constant number of fluorescent beads added to well/
number of fluorescent beads counted). The percentage
leukemia cells surviving in wells with effector cells was
calculated with the following formula: Percentage
leukemia cells surviving 5 (number of leukemia cells
in well with effectors/number of leukemia cells in wells
without effector cells) 100.Duplicates or triplicates of
each condition were measured.
ELISPOT
Splenocytes (106) were added to wells preincubated
with interferon-gamma (IFN-g) capture antibody and
stimulated for 48 hours with HY peptides (Uty,
Dby, and Smcy) or irrelevant peptide (WPRPQIPP) (5
mg/well) [6]. IFN-g release was detected with biotiny-
lated anti-IFN-g antibody (Caltag, Burlingame, CA)
and streptavidin peroxidase.
Flow Cytometry
Conventional analytic flow cytometry was per-
formed using a Becton Dickinson FACScan with anal-
ysis performed by Cellquest software or WinMDI.
Directly labeled monoclonal antibodies for the cell
surface markers specified in the text were obtained
from Pharmingen (San Diego, CA) or Caltag.
ELISA
U-bottomed 96-well plates were incubated over-
night at 4Cwith blocking buffer (balanced salt solution
with 0.05%Tween, 1mMTween 20, and 0.25%bovine
serum albumin). After washing, 106 leukemia cells or
normal spleen cells were incubated for 60 minutes at
4C in each well with 95 mL flow cytometry buffer
(Streck, Omaha, NE) and 5 mL experimental animal se-
rum.Followingwashingcellswere incubated for60min-
utes at 4C in buffer containing 1:200 dilution of
biotinylated goat antimouse immunoglobulin (BD
Pharmingen). Following washing, cells were incubated
for 1 hour in ice-cold buffer with a 1:1000 dilution of
alkalinephosphatase-streptavidin (BDPharmingen).Af-
ter washing, cells were incubated in 100 mL of PNPP
substrate for 10 minutes. The colorimetric reaction
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sity (O.D.) wasmeasured at 405 nmwith anELISAplate
reader.
Statistics
Datasets were assessed for normal distribution by
Kolmogorov-Smirnov tests. For normally distributed
data, 2-tailed t-tests were performed to compare means.
For data that were not normally distributed, 2-tailed
nonparametric Mann-Whitney tests were performed
to compare medians. Survival curves were compared
with the log-rank test. Association of antibody levels
with categoric outcomes in vivo was assessed with chi-
square tests. Statistical calculations were performed us-
ing GraphPad Prism 4.03 and R 2.5 software packages.RESULTS
Vaccination Enhances Antigen-Specific T Cell
Responses in Transplant Recipients Receiving
DLIs
The overall goal of this work was to test the hypoth-
esis that vaccination of the transplant recipient receiving
DLI would enhance control of residual acute leukemia.
To test this, we used experimental acute leukemias
derived from male mice in which immunologically
well-characterized male HY minor histocompatibility
antigens served as leukemia-specific antigens. Female
donors and female recipients were used for transplanta-
tion, allowing us to discriminate between allogeneic im-
mune responses that were leukemia specific versus thoseFigure 1. Concurrent vaccination with HYantigen-positive recipient strain ce
not increase T cell responses to widely distributed recipient minor histocompa
cinated with male C57BL/6 spleen cells. One day later, some groups received 5
SPOTassays were performed using peptide antigens to stimulate spleen cells fro
splenocytes represent5 (spots inwells withHYpeptides) – (spots inwells with
transplantation groups: BMTonly (n5 7), DLI (n5 12), DLI1Vac (concurrent v
control was female donor strain C3.SW primed against male C3.SW (n 5 4).
standard error of the mean. HY-specific spots in DLI 1 vaccination group ar
test). DLI1 vaccination group is significantly greater than vaccination-only grou
dent experiments. (B) Recipientminor histocompatibility antigen–specific ELISP
H7, and H13minor histocompatibility peptides) – (spots in response to irreleva
were no differences between any of the transplant groups (DLI1 vaccination n
from 2 independent experiments. The positive control was donor strain C3.SWdirected against widely distributed minor histocompat-
ibility antigens.
The first experiments measured the impact of vacci-
nation on antigen specific T cell responses following
DLI. One month following allogeneic BMT, female
C57BL/6 recipients were infused with splenocytes
from female C3.SW donor strain mice. Some groups
also received vaccination with male C57BL/6 cells 1
day prior to DLI. Two weeks later, INF-g ELISPOT
assays were performed to measure HY peptide–specific
Tcell responses.Figure1Ademonstrates thatDLIalone
or vaccination alone induced negligible HY-specific
responses. However, the combination of vaccination
with DLI produced significantly greater HY-specific
responses in the allogeneic transplant recipients. Similar
experiments were performed measuring INF-g ELI-
SPOT responses to widely distributed recipient strain
(C57BL/6) minor histocompatibility antigens (H3,
H7, and H13). Consistent with our earlier published
findings, vaccination did not induce significant T cell
responses to these ubiquitously distributed antigens
(Figure 1B).
Combining Vaccination with DLI Does Not
Substantially Improve Long-Term Survival
Compared to Treatment with DLI Alone
Based on the observation that coupling vaccination
with DLI substantially increased the type I T cell re-
sponses against the HY antigens on the leukemia cells,
we performed experiments in vivo to determine if
treatment with vaccine-augmented DLI could exertlls with allogeneic DLI increases T cell responses to HYantigens but does
tibility antigens. One month after transplantation, some mice were vac-
 106 CD90.2 selected female strain DLIs. Two weeks later, INF-g ELI-
m the animals. (A) HYantigen specific ELISPOT. HY-specific spots per 106
irrelevant peptide). Average specific spots are presented for the following
accination andDLI, n5 25), and Vac (vaccination, noDLI, n5 4). Positive
Negative control was a normal C57BL/6 female (n 5 2). Error bars are
e significantly greater than DLI-only group (P 5 .008 by Mann-Whitney
p (P5.0341 by Mann-Whitney test). Results are pooled from 5 indepen-
OT. Specific spots per 106 spleen cells5 (spots in response to pooledH3,
nt peptide). Average and standard error of the mean are displayed. There
5 9, DLI n5 2, vaccination n5 7, BMTonly n5 3). Results are pooled
previously immunized with recipient strain C57BL/6 cells.
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kemia. In pilot studies, we performed short-term as-
says of leukemia growth by measuring the percentage
of leukemia in marrow and survival 2 weeks after leu-
kemia challenge and treatment. One month after allo-
geneic transplantation, mice were injected i.v. with 104
ALL cells derived frommale C57BL/6mice. Themale
HY antigens serve as leukemia-restricted antigens in
this model. In our experience this dose of leukemia
cells uniformly produces death from leukemia in fe-
male mice within 1 month. One day after leukemia
challenge, experimental mice were vaccinated with
107 irradiated male recipient strain C57BL/6 spleen
cells. One day later, they received i.v. infusion of 107
CD90.2 selected spleen cells from donor strain
C3.SW females that had been sensitized to HY anti-
gens by vaccination with C3.SW male cells. Two
weeks later, leukemia burden in marrow was measured
by flow cytometry. Animals treated with vaccine-aug-
mented DLI or DLI alone had significantly less leuke-
mia compared to untreated control mice (Figure 2).
Having seen biologically meaningful antileukemia
effects in these pilot studies, we performed a large
long-term survival study designed to ask whether vac-
cine augmented DLI led to greater survival than DLI
alone. The experiment was designed to have 80%
power to detect a 15-day difference in survival. One
month following allogeneic transplantation, miceFigure 2. Short-term leukemia burden is reduced in BMT recipients
treated with vaccine-augmented DLI. One month after allogeneic trans-
plantation, mice were injected i.v. with 104 ALL cells. One day later, the
‘‘DLI and Vac’’ group was vaccinated with 107 irradiated male recipient
strain spleen cells. Two days after leukemia cell injection, mice in the
‘‘DLI’’ and ‘‘DLI and Vac’’ groups received DLI at a dose of 107 cells.
Mice were followed daily. Starting at 10 days, some mice appeared mor-
ibund. Animals were euthanized when moribund or at 2 weeks after leu-
kemia injection. When animals were moribund or at 2 weeks after
leukemia injection, leukemia cell burden was measured by flow cytom-
etry in femur bone marrow. Bars represent average and standard error
of the mean for the groups. Control mice (n5 8) received no treatment.
‘‘DLI and Vac’’ mice (n 5 10) received vaccine-augmented DLI. ‘‘DLI’’
mice (n 5 3) received only DLI. P values for comparisons between
groups are presented. In marrow, percentage leukemia was significantly
less in ‘‘DLI 1 Vac’’ group (P 5 .006 by Mann-Whitney test).were challengedwith 104maleALLcells.Oneday later,
the experimental group was vaccinated with male ALL
cells. The following day, mice in both the experimental
and control groups received an infusion of 107 CD90.2
selected spleen cells from donor strain C3.SW females
that had been sensitized to HY antigens by vaccination
with C3.SWmale cells. Mice did not receive additional
vaccinations or DLIs. They were followed for survival
for up to 73 days, at which time surviving mice were
euthanized. At death, necropsy was performed to assess
cause of death. Twenty-two percent of 18 mice treated
with vaccination/DLI survived, and median survival
was 46 days. In the group treated with only DLI
(n 5 17), 11% were survivors, and median survival
was 37 days (Figure 3A). The differences were not sta-
tistically significant. The causes of death were similar inFigure 3. Survival after leukemia challenge in mice treated with
vaccine-augmented DLI or DLI alone. (A) Single treatment with DLI
and/or vaccine. One month after allogeneic transplantation, mice
were infused i.v. with 104 male ALL cells. One day later, 1 group was vac-
cinated with male ALL cells. Two days after ALL cell challenge, all mice
received 107 CD90.2-enriched spleen cells from HY antigen–primed
C3.SW donors as DLI treatment. ‘‘*’’ indicates the time of the treatment
with vaccine and DLI. Mice were followed for survival. The modest in-
crease in survival in the DLI/vaccine group was not statistically significant
(P 5 .28 by log-rank test; DLI/Vac group n 5 18, DLI-only group
n 5 17). (B) Treatment with 2 courses of vaccine and/or DLI. In an in-
dependent experiment, the treated animals received vaccine 1 day after
ALL challenge and DLI 2 days after ALL challenge. The treatments were
repeated 9 days later, with another treatment with vaccine 10 days after
ALL challenge and DLI 11 days after ALL challenge. In this Experiment 2,
additional groups were included: a no-treatment group (‘‘None’’) and
a vaccine-only group (‘‘Vac’’). There were no significant differences in
survival between groups as assessed by the log-rank test.
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died from leukemia, whereas 2 died of GVHD. Two
mice survived, and by body appearance and liver histol-
ogy did not have active GVHD. In the vaccine-aug-
mented DLI group, 14 mice died; 12 died of
leukemia, whereas 2 died of GVHD. Among the 4 sur-
vivors, none had body features suggestive of severe
GVHD, whereas 2 of the 4 hadmoderate histologic ev-
idence of liver GVHD.
A limitation of this experiment was that animals
were treated only once with vaccine and DLI. Al-
though this experimental design consistently increased
the activity of HY-specific donor T cells in vivo, it may
have been quantitatively inadequate to control leuke-
mia in a survival experiment. The survival trial was re-
peated, but transplant recipients were treated twice:
once as before and again 9 days later. The transplant
recipients were followed for 58 days after leukemia
challenge, at which time the survivors were euthanized
and examined by flow cytometry for residual leukemia.
The outcome was the same (Figure 3B). Approxi-
mately half the transplanted animals survived, but
there was no difference in survival between the groups.
Only 1 of 21 surviving mice had flow-detectable leuke-
mia in the marrow; the limit of detection was 0.1%
(data not shown).
Relapsing Leukemia Cells Retain Sensitivity to
Antigen-Specific Cytolytic T Cells
Because we had repeatedly observed in these exper-
iments and other experimental models significant
enhancement of antigen-specificT cell activity by vacci-
nation coupled with DLI, we were puzzled by the very
modest impact concurrent vaccination had on survival.
One simple hypothesis for the finding would be loss ofFigure 4. HY-positive male ALLs that exhibited progressive growth in allogen
remain fully sensitive to donor cytolytic cells specific for HYantigens. Donor str
cells restimulated for 4 days in vitro with HY peptides. Cytolytic effector cells w
target ratio of 50:1. Three days later, the number of viable leukemia cells was
a female recipient strain ALL cell line. The positive control target was the male
reisolated from animals treated only with DLI are labeled ‘‘D#’’ and those fro
labels, ‘‘#’’ refers to the unique identifier for an animal in the experiment. ‘‘Perc
cells in wells with cytolytic cells)/(number of viable leukemia cells in wells withleukemia cell sensitivity to cytolytic T cells. This has
been observed in numerous tumor immunology sys-
tems. Because we had reisolated leukemia cells from
many of the animals at time of death, we were able to
test this hypothesis. Resistance to antigen-specific T
cells can occur if cells cease to express MHC molecules
that present the target antigen. In the HY system, the
Uty and Smcy antigen peptides are presented by
H2-Db. We examined H2-Db expression by flow
cytometry but found no reduction in H2-Db in the
ALL cells that progressed in vivo (data not shown).
Other mechanisms of acquired resistance could be loss
of antigen expression or defects in apoptotic responses
to cytolytic T cells. We tested these possibilities by
examining the leukemias reisolated from animals after
allogeneic DLI treatment for sensitivity to cytolytic T
cells specific for HY antigens. Leukemia cells were
cocultured with HY-specific CTLs, and after 3 days,
the number of surviving leukemia cells was measured
by flow cytometry. Figure 4 demonstrates that all of
the leukemia reisolates remained sensitive to the
CTLs (P \.01 by Student’s t-test compared to the
insensitive female leukemia antigen-negative control
target). There was no difference in sensitivity between
the reisolates from the 2 experimental groups (DLI
group 29.1 6 2.9% average 6 SEM survival, DLI 1
vaccine group 30.76 3.2%, P 5 .75 by t-test).
Long-Term Transplant Survivors Have Evidence
of B Cell Immunity
Although we did not observe a large increase in the
efficacy of DLI provided by concurrent vaccination in
either long-term survival study, we did see survivors in
both experiments. In Experiment 1, 17% of all chal-
lenged animals survived without signs of disease untileic transplant recipients treated with DLI with and without vaccination
ain cytolytic cells were generated fromHY-primed female C3.SW spleen
ere mixed with leukemia cells in triplicate microcultures at effector-to-
measured by flow cytometry. The negative control leukemia target was
ALL cell line that was injected into the animals prior to DLI. Leukemia
m animals treated with DLI and vaccination are labeled ‘‘DV#.’’ In these
ent survival’’ is plotted and was calculated as (number of viable leukemia
out cytolytic cells). Average and standard error of the mean are plotted.
Figure 5. INF-g ELISPOTresponses to leukemia-restricted HYantigens and to widely distributed recipient minor histocompatibility antigens in long-
term leukemia survivors. Seventy-three days after leukemia challenge, survivors with no evidence of active leukemia were euthanized, and INF-g ELI-
SPOTassays were performed on splenocytes of individual animals. In the top panels, responses to HY peptides (A) Dby and (B) Uty are displayed. In the
lower panels, responses to the ubiquitously distributed C57BL/6 minor histocompatibility antigens (C) H3, (D) H7, and (E) H13 are displayed. Average
and standard errors of the mean for the animals receiving DLI alone and for those receiving both vaccination and DLI are displayed. The positive control
for the HY ELISPOTs was a female C57BL/6 primed against male C57BL/6 cells. The positive control for the ubiquitous C57BL/6 minor antigen ELI-
SPOTS was a C3.SW mouse primed against C57BL/6 cells. Dby responses in DLI/vaccine-treated mice (n 5 4) compared to DLI-only mice (n 5 2)
by 2-tailed t-test yielded P 5 .077. Similar comparison of Uty responses yielded P 5 .082.
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fromall surviving animalswereplaced in culture to allow
outgrowth of minimal residual leukemia. In none of the
6 survivors did we see leukemia emerge in cultures over
a 2-week period (data not shown). In Experiment 2 52%
of all animals (21 of 40) survived until day 58.Only 1 had
leukemia detectable by flow cytometry in their marrow.
The dose of leukemia cells used in these experiments is
uniformly fatal in normal C57BL/6 mice.
In both survival experiments, we performed some
immune function assays to learn if there was any evi-
dence that immunitymayhaveplayed a role inmaintain-
ing the remission of leukemia in the survivors. In
Experiment 1, we were unable to detect HY-specific cy-
tolytic T cells in the survivors following 4-day in vitro
restimulation with irradiated male spleen cells (data
not shown). However, using more sensitive ELISPOT
assays, we did observe very modest HY peptide–specific
(Uty and Dby) INF-g release in spleen cells in 4 of 4
animals treated with vaccination and DLI (Figure 5A
and B). We did not see similar responses in the 2
surviving animals treated with DLI only. We did not
see significant INF-g responses to the recipient strainminor histocompatibility antigens H3, H7, and H13
the survivors (Figure 5C, D, and E). In Experiment 2,
none of the 21 survivors had evidence of either
HY peptide–specific or alloantigen peptide–specific
INF-g responses (data not shown).
Our failure to find evidence of a robust T cell
memory response in the majority of survivors sug-
gested several possibilities. One possibility was that
the T cell response occurred earlier in the experiment
and waned to near undetectable levels by the time the
surviving animals were assessed 2months later. Leuke-
mia was either completely eradicated by this wave of T
cells or was not completely eradicated, and that ani-
mals with residual leukemia relapsed after the T cell
response ceased. This interpretation would be com-
patible with the typical kinetics of a T cell response
and the timing of relapse death that started to be
observed after day 25. An alternate possibility was
that non-T cell responses may have contributed to
control of leukemia.
In the first survival experiment at the time of eutha-
nasia, small amounts of serum had been obtained from
surviving transplant recipients and pooled. A pilot
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any evidence of a B cell antibody response that
recognized leukemia cells. ALL cells were incubated
in dilutions of normalmouse serum or survivors’ serum.
Fluorochrome labeled antimouse IgG or antimouse
IgM was used as a second step, and flow cytometry
was performed. Figure 6 demonstrates detection of
IgM and IgG binding antibodies at dilutions of 1:40
or greater in survivors’ serum. Specificity of the anti-
bodies was explored using a large panel of malignant
and nonmalignant cells chosen to help discern whether
the antibodies were broadly reactive against hematopoi-
etic cells or restricted to some feature of the NSTY
ALL cells used to challenge the mice. The ALL cells
were (1) male, (2) GFP positive, (3) contained a human
bcr-abl gene, (4) C57BL/6 in origin, and (5) malignant
(Figure 7 and Table 1). The pooled serum had broad
but not universal reactivity, suggesting that the antibody
response was not restricted to 1 of these features.
The pilot study could not address the question of
whether the antibodies were induced by alloreactivity
alone and/or by the posttransplant vaccination. To
further address the question of whether an antibody re-
sponse that recognized ALL cells could be produced by
active graft-versus-host alloreactivity alone, we analyzed
another independent experiment in which mice that had
undergone allogeneic transplantation in which donors
had been previously vaccinated against normal C57BL/
6 recipient strain spleen cells to enhance alloreactivity
and survived challenge with ALL. These mice had not
received posttransplant vaccination against leukemia or
normal cells. Eighty-five days after allogeneic transplan-
tation, we collected serum from tail vein sampling from
10 living mice that had survived challenge with 106Figure 6. Serum from leukemia survivors contains IgM and IgG antibodies t
diluted normal pooled mouse serum or serum pooled from mice that were leuk
mouse IgG (right panel) was then used to detect cell surface bound antibody b
and 1:20. IgG antibodies were also detected at 1:10, 1:20, and 1:40 dilutions.ALL cells on day 5 after transplantation. Instead of
flow cytometry, ELISAwas used to detect antibodies be-
cause this technique was more sensitive and more quan-
titative. Figure 8 demonstrates that 9 of 10 mice had
evidence of antibodies that bound ALL cells. To test
whether posttransplant vaccination could also contribute
to an antibody response, an independent experiment was
performed in which allogeneic transplant recipients that
had not been challenged with live ALL cells were vacci-
nated against either NSTY ALL or another C57BL/6
acute leukemiaC1498. Figure 9 demonstrates that vacci-
nated mice had antibodies that bound the leukemia cells
against which they were vaccinated.
Leukemia-Free Survival Is Associated with
Antibody Responses
The first survival study experiments did not shed any
light on the question whether the antibody response was
related to survival. To address this question in survival
Experiment 2, we systematically sampled serum from
all transplant recipients at 3 time points: 1 month after
transplantation but before challenge with leukemia and
treatment, 3 weeks after leukemia challenge and treat-
ment, and at day 58, when all long-term survivors were
euthanized. ELISA for antibodies bindingNSTY leuke-
mia cells was performed for all samples. In addition,
ELISA for antibodies binding normal donor C3.SW
and normal recipient C57BL/6 splenocytes was per-
formed on all survivors because we had more serum.
Figure 10A demonstrates that leukemia reactive anti-
bodies were significantly greater in survivors compared
to those animals that died of leukemia.The survivors’ se-
rumexhibited some cross-reactivitywith normalC3.SW
donor and recipient C57BL/6 spleen cells (Figure 10B).hat bind to NYST ALL cells. NYST leukemia cells were incubated with
emia survivors. PE-labeled secondary antimouse IgM (left panel) or anti-
y flow cytometry. IgM antibodies were also detected at dilutions of 1:10
Figure 7. Assessment of cellular specificity of antibody responses in serum from leukemia survivors. Pooled serum from surviving mice diluted to 1:20
was added to avarietyof cell types (described inTable 1A) anddetectedwith either PE-labeled secondary antimouse IgMor antimouse IgG.Normalmouse
serumdiluted 1:20was used as a control. The shaded histogram represents the normal serumcontrol, whereas the unfilled histogramoverlay is the serum
from the ALL survivors. Forward and side scatter characteristics were used to gate on viable cells for the leukemia lines. For normal marrow, similar
scatter characteristics were used to positively gate on mononuclear cells, whereas CD19-positive normal B cells were excluded from analysis.
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Figure 8. Detection of antibodies that bind an independently derived
female leukemia line in animals that had undergone allogeneic transplan-
tation and had survived challenge with leukemia cells. Four days after al-
logeneic transplantation, mice were challenged with 106 female NYST-1
ALL cells. Twomonths later, serum from individual animals was obtained
from tail vein puncture and used at a 1:20 dilution in a cellular ELISA as-
say designed to detect antibodies on NYST-1. Antibodies were detected
by a biotinylated polyclonal goat anti-mouse immunoglobulin followed
by a streptavidin-alkaline phosphatase reagent. Optical density of the en-
zymatic conversion of PNPP is plotted. The negative control is serum
from a normal C57BL/6 mouse. The positive control is a 1:100 dilution
of a mouse monoclonal antibody specific for H2-Db. Figure 9. Detection of antibodies binding leukemia lines found in allo-
geneic transplant recipients vaccinated against C57BL/6 leukemias. Mice
that had undergone allogeneic transplantation but had not been chal-
lenged with live leukemia cells were vaccinated against either irradiated
NSTYor C1498 cells in adjuvant. Serum from individual animals (n5 3)
was used in a qualitative ELISA assay for detection of antibodies that
bound either C1498 or NSTY. Serum from a mouse (n5 1) that had un-
dergone allogeneic transplantation but had neither been vaccinated nor
challenged with viable leukemia was used as a control. Optical density in
the ELISA is plotted.
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ples demonstrated that the serum concentration of the
antibodies was fairly significant, with an average
dilution of 1:92, producing 50% maximum O.D. values
in the assays. (In comparison, commercial-grade mono-
clonal antibody directed at H2-Db in a stock concentra-
tion of 0.5 mg/mL diluted at 1:750 produced 50%
maximum O.D. in the same assays.)
This analysis compared antibody levels from survi-
vors at the end of the experiment to the last sampled
antibody level in animals that died of leukemia. We
conducted another analysis to address the question of
whether antibody levels at the first time point (4 weeks
after allogeneic transplantation but before injection
with leukemia cells) had any relationship with the risk
of later death from leukemia or GVHD. Outcomes
for each animalwere categorized as alive, dead from leu-
kemia, dead fromGVHD, or dead of unspecified cause.
Antibody levels for each animal were categorized as
above or below the median for the entire experimental
population. Chi-square analysis demonstrated a statisti-
cally significant relationship between outcome and anti-
body level at the time of leukemia challenge (Table 2).
Few animals with high antibody levels died of leukemia
(P5 .0197). In comparison of death from leukemia with
death fromGVHD, higher antibody levels were associ-
ated with death fromGVHD (P5 .0099). A statistically
significant difference was not observed between survi-
vors and death from GVHD; however, the death fromGVHD group was small (n 5 5), limiting the power
of the analysis.DISCUSSION
Our initial goal was to determine if coupling active
vaccination with ALL cells with DLI would improve
immunologic control of ALL in recipients of alloge-
neic HSCT. The basis for this approach was our
previous demonstration that coupling of active vacci-
nation at the time of adoptive lymphocyte transfer
substantially increased the number of antigen-specific
T cells in recipients. We learned that vaccination did
increase the frequency of the desired antigen-specific
cells in transplant recipients treated with DLI. We
also learned that this combined treatment did not in-
crease the frequency of donor T cell responses to ubiq-
uitously expressed recipient minor histocompatibility
antigens, or the incidence of clinical GVHD as judged
by mortality or histologic assessment of GVHD.
However, despite these increases in the activity of
Figure 10. Antibody levels in long-term survivors compared to those in animals dying from leukemia. Serum sampleswere taken from all animals in survival
Experiment 2, 4 weeks after transplantation but before leukemia challenge, 3 weeks after leukemia challenge, and for those animals surviving until day 58,
when the experiment was ended. Control serumwas obtained from normal C57BL/6mice. ELISAwas performed using NSTY leukemia cells for all samples.
ELISAwas also performedusingC3.SWorC57BL/6 splenocytes for the samples from long-termsurvivors.All ELISAswere performedusing a 1:20 dilutionof
the serum. (A)Higher levels of antibodies bindingNSTY leukemia are present in long-term survivors compared to those present in animals dying of leukemia.
Each dot represents a single animal. For survivors, the serumwas that at the last sample on day 58. For the animals dying of leukemia, the serumwas that last
sampled at 3 weeks after leukemia inoculation. Horizontal lines represent the average. Significantly higher O.D. levels are present in survivors compared to
thosedyingof leukemia (t-test P\.0001), ornormalC57BL/6mice (t-test P5.001). Therewasnodifferencebetweenanimals dying from leukemia andnormal
C57BL/6 mice (t-test, P5.76). (B) Survivor serum exhibits crossreactive binding with normal splenocytes. ELISAwas performed using 1:20 dilutions of sur-
vivor serum on NSTY leukemia cells, C3.SW, or C57BL/6 spleen cells. In addition, assays were also performed using normal C57BL/6 serum and C57BL/6
splenocytes. Each dot represents a single animal, and horizontal lines are the averages. O.D. values using survivor serumonC57BL/6 andC3.SW splenocytes
are significantly greater than values using normal C57BL/6 serum (t-tests, P\.001 for each comparison).
Table 1. Binding of Antibodies in Serum of Leukemia Survivors to a Panel of Murine Hematopoietic Cells
A. Characteristics
Cell Malignant/normal Male/female GFP bcr/abl Strain IgM IgG
NSTY1 leukemia female GFP+ bcr/abl+ C57BL/6 + ND
NSTY2 leukemia female GFP+ bcr/abl+ C57BL/6 + ND
NSTY3 leukemia female GFP+ bcr/abl+ C57BL/6 + ND
NSTY6 leukemia male GFP+ bcr/abl+ C57BL/6 + +
NSTY7 leukemia male GFP+ bcr/abl+ C57BL/6 + ND
fAML leukemia female GFP+ bcr/abl+ C57BL/6 - +
mAML leukemia male GFP+ bcr/abl+ C57BL/6 - +
ASLN-GFP leukemia female GFP+ bcr/abl+ C57BL/6 + +
C1498-GFP leukemia female GFP+ negative C57BL/6 - +
ASLN leukemia female negative bcr/abl+ C57BL/6 - -
C1498 leukemia female negative negative C57BL/6 + +
female C57BL/6 marrow normal female negative negative C57BL/6 - -
male C57BL/6 marrow normal male negative negative C57BL/6 - -
female C3.SW marrow normal female negative negative C3.SW - -
YAC leukemia female negative negative A/Sn + -
P815 leukemia female negative negative DBA/2 + +
B. Summary
Classification IgM Positive IgG Positive
NSTY series ALL 5/5 1/1
Not NSTY series ALL 4/7 7/11
ALL 6/7 3/3
Not ALL 3/9 5/9
BCR-ABL 6/9 5/5
Non BCR-ABL 3/4 3/4
GFP 6/9 5/5








Cells were incubated with normal mouse serum or pooled serum from leukemia survivors at a dilution of 1:20, followed by incubation with PE-labeled anti-
IgM or anti-IgG. Flow cytometry was then performed, and individual histograms are presented in Figure 7. (A) ‘‘Cell’’ is the cell line or tissue examined.
‘‘Malignant/normal’’ indicates whether the cells were malignant cell lines or normal tissues. ‘‘Male/female’’ indicates the sex of the animal from which the
cell line or tissuewas derived. ‘‘GFP’’ indicates whether the cells contain a green fluorescent protein gene or not. ‘‘bcr/abl’’ indicateswhether the cells contain
a human bcr/abl gene. ‘‘Strain’’ indicates themouse strain fromwhich the cell line or tissuewas derived. ‘‘IgM’’ and ‘‘IgG’’ indicate that cell-binding antibodies of
this isotype were detected in serum from leukemia survivors. (B) Summary of IgM or IgG reactivity based on features of cells described in (A).
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Table 2. Outcomes as a Function of Leukemia-Reactive Antibody Levels
Outcome Low Antibody High Antibody Total
(A) Alive 9 12 21
(B) Dead from leukemia 8 1 9
(C) Dead from GVHD 1 4 5
(D) Dead, cause undetermined 2 3 5
Totals 20 20 40
Chi-square analysis
Comparison P-Value
Overall, all groups .0487
Alive (A) versus dead from leukemia (B) .0197
Dead from GVHD (C) versus dead from leukemia (B) .0099
Alive (A) versus dead from GVHD (C) .3451
Dead from leukemia (B) versus (A, C, and D) .0047
GVHD indicates graft-versus-host disease.
Low antibody indicates the antibody level was below the median; high antibody indicates the antibody level was above the median; dead from leukemia
indicates animal had exhibited symptoms of acute leukemia prior to death (rear leg paralysis, lymphadenopathy) or at necropsy had massive splenomeg-
aly or >25% marrow leukemia as measured by flow cytometry; dead from GVHD indicates the animal had clinical evidence of GVHD prior to death
(weight loss, hair loss) and at necropsy did not have splenomegaly or detectable leukemia in marrow as measured by flow cytometry; dead, cause un-
determined was death not meeting the diagnostic criteria for either death from leukemia or death from GVHD.
Chi-square analysis was initially performed upon the entire dataset (‘‘Overall, all groups,’’ 2 4 analysis). Having found a statistically significant difference
additional 2  2 chi-square comparisons were performed between the specified groups.
One month after transplant but immediately before challenge with leukemia and before treatment with vaccination and/or DLI, peripheral blood was
sampled. ELISA for leukemia reactive antibody was performed. Median O.D. for all animals was 0.93.
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increase in long-term survival when active vaccination
was added to DLI. The failure was not because of
acquired resistance to cytolytic T cells by the leukemia
cells. These studies do not provide clear mechanistic
explanations for the failure to improve acute leukemia-
free survival in these experiments. We speculate that
the kinetics of acute leukemia population in vivo may
have simply outpaced the more limited expansion of
antileukemia T cells in vivo.
Although our studies did not show improvements
in survival between the experimental and control
groups, they did demonstrate that there were a signifi-
cant number of long-term survivors in both groups.
These animals did not have clinical GVHD. We per-
formed studies on survivors exploring the hypothesis
that survivors would have evidence of T cell immunity
that would have activity against leukemia cells. This
hypothesis is compatible with the dominant paradigm
in transplantation immunology that donor T cells are
the initiators and frequently the mediators of GVL
effects. To our surprise, we were not able to detect ro-
bust cytolytic activity in these survivors when their
splenocytes were restimulated in vitro in conventional
cytolytic T cell culture assays (data not shown). More
sensitive ELISPOT assays on directly assayed spleno-
cytes demonstrated only modest levels of HY antigen–
specific T cell activity in a minority of survivors.
After failing to see evidence of robust long-term T
cell immunity in the survivors, we screened the serum
for antibodies to leukemia cells. To our surprise, the
experiments provided evidence of both IgM and IgG
antibodies that bound a variety of leukemia cells. Theantibodies were not specific for the leukemia used
to challengeor vaccinate the transplant recipients.How-
ever, the cross-reactivity did not correlate with single
variables such as sex, presence of green fluorescent
protein or bcr/abl genes, or strain of cell origin, and
thus cannot be dismissed as an artifact. These serum an-
tibodieswere likely tohave beenpolyclonal, and thus the
observation that reactivity did not neatly segregate with
these variables does not ruleout the possibility that some
of the antibodiesmay have reacted with epitopes related
to these variables. However, the observation that there
was evidence in the ELISA assays that the serum
antibodies were reactive with nonmalignant C57BL/6
and C3.SW spleen cells suggests the hypothesis that in
these transplants, there was generation of some autoim-
mune or autoreactive antibodies.
In these studies, we observed leukemia binding
antibodies in an independent cohort of mice that had
undergone highly alloreactive HSCT and had survived
challenge with an independently derived ALL line, in-
dicating that active vaccination is not necessary for the
development of these antibodies when there is active
alloreactivity. However, vaccination after allogeneic
transplantation was also shown to induce antibody re-
sponses. Thus, both vaccination and active alloreactiv-
ity induce antibody responses that bind leukemia cells.
These studies do not answer the question ofwhether
the antibodies we found played a causal role in immune
control of leukemia. However, statistical analysis in the
second survival experiment did demonstrate a strong
correlation between leukemia-free survival and higher
antibody levels.There is ample precedent for circulating
antibodies having significant impact on normal and
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a key pathologic role in autoimmune hemolytic anemia,
immune thrombocytopenia, and autoimmune neutro-
penia [15,16]. Monoclonal anti-CD20 has a clear role
in the treatment of B lineage lymphomas [17,18].
Antibodies to minor histocompatibility antigens and
nonpolymorphic hematopoietic antigens have been
identified in some studies of human GVHD [19-22],
especially chronic GVHD (cGVHD) [23,24]. Active
cGVHD has been associated with evidence of B cell
activation [25,26].
In summary, the work described here demonstrates
that in a murine model of allogeneic MHC-matched
HSCT for high-risk ALL, an allogeneic GVL effect
that involves both T cell and B cell responses can be as-
sociatedwith long-termcontrol of leukemia.Our obser-
vations in this system indicate that immune therapies
based on transient increases in cytolytic T cell activity
alone are unlikely to produce dramatic improvements
in disease control. However, immune interventions de-
signed to increase both T cell and B cell responses
may be worthy of further consideration. Our current
work is exploring at a mechanistic level whether the an-
tibody responses we observe in transplant survivors play
a significant role in control of leukemia and how B cell
responses interactwithTcell responses in the posttrans-
plant immune environment.ACKNOWLEDGMENTS
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